The etiology of Alzheimer's disease is now known to be multifactorial. The genetic factors transferrin C2 (TfC2) and apolipoprotein E epsilon 4 (ApoE-epsilon 4) have both been associated with Alzheimer's disease (AD). Transferrin is the carrier protein for iron in the blood, while ApoE is involved with the transport and redistribution of lipids. In the present study, the polymerase chain reaction (PCR) method was used to determine the frequency of both TfC2 and ApoE-epsilon 4 in 27 AD patients, 9 vascular dementia (VaD) patients, and 27 controls. Patients were diagnosed according to the criteria as set out in the 4th edition of the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV). The frequency of the TfC2 allele for the AD patients was 24%, while for the VaD patients it was 12.5%, which was not significantly different from the controls at 13%. The frequency of ApoE-epsilon 4 for the AD patients was 44%, for the VaD patients 22%, and controls 17%. Of the 27 AD patients, 8 had both TfC2 and ApoE-epsilon 4. The age of onset of the disease in these 8 patients (51-67 years, mean 60.25) was significantly earlier (p < 0.02) than in the remaining AD patients (49-76 years, mean 66.9). None of the VaD patients had both the TfC2 and the ApoE-epsilon 4 alleles.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1749-6632.2000.tb06369.x | DOI Listing |
Multimed Man Cardiothorac Surg
January 2025
Congenital Heart Center, Division of Cardiovascular Surgery, Department of Surgery, University of Florida, Gainesville, FL, USA.
The Berlin Heart EXCOR is a pulsatile paracorporeal ventricular assist device (VAD) for neonates, infants, children and adults with congenital or acquired severe ventricular dysfunction. Berlin Heart EXCOR VADs are routinely used as either a bridge to a cardiac transplantation, or occasionally as a bridge to ventricular recovery. Our programmatic philosophy is to bridge neonates and infants with functionally univentricular ductal-dependent systemic circulation or functionally univentricular ductal-dependent pulmonary circulation who are at high risk for staged palliation because of important cardiac risk factors with a single-ventricle VAD (sVAD) as a bridge to a cardiac transplant.
View Article and Find Full Text PDFRev Cardiovasc Med
January 2025
Center for Preclinical Surgical & Interventional Research, The Texas Heart Institute, Houston, TX 77030, USA.
The evolution of left ventricular assist devices (LVADs) from large, pulsatile systems to compact, continuous-flow pumps has significantly improved implantation outcomes and patient mobility. Minimally invasive surgical techniques have emerged that offer reduced morbidity and enhanced recovery for LVAD recipients. Innovations in wireless power transfer technologies aim to mitigate driveline-related complications, enhancing patient safety and quality of life.
View Article and Find Full Text PDFAntibiotics (Basel)
January 2025
Unit II, Department of Infectious Diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, 20157 Milan, Italy.
: Vascular access device (VAD)-associated infections, including catheter-related (CRBSI) and catheter-associated bloodstream infections (CABSI), present significant challenges in patient care. While multidisciplinary VAD teams (VATs) are equipped with protocols for managing these infections, adherence to these guidelines in real-life practice is inconsistent. This study aims to evaluate the alignment between actual VAD infection management practices and VAT-recommended protocols.
View Article and Find Full Text PDFDeath Stud
January 2025
Australian Centre for Health Law Research, Queensland University of Technology, Brisbane, Australia.
This research, undertaken in Queensland, Australia aimed to explore community members' knowledge of voluntary assisted dying (VAD) 17 months after it became a lawful option. Adults living in Queensland ( = 1000) completed an online survey about knowledge of VAD as a legal option and awareness of how to access VAD and information about it. Quotas were set for age, gender and geographical region within Queensland.
View Article and Find Full Text PDFJ Heart Lung Transplant
January 2025
Department of Pediatrics, Medical College of Wisconsin and Herma Heart Institute, Children's Wisconsin, Milwaukee, Wisconsin.
Background: The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) began in 2018 as a collaborative learning health system committed to improving outcomes in pediatric heart failure, including children and adults with congenital heart disease, supported with ventricular assist devices (VADs). This report describes patient and device characteristics, and outcomes through 1-year post-implant.
Methods: The ACTION VAD registry report was created from data submitted to the ACTION learning network from April 2018 to June 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!